knowledge -WSS

knowledge

author：knowledge 2025-09-28 21:54:19 - browse：88

Fran van Delft for Galapagos

Seeking to differentiate itself from other makers of CAR-T cancer therapies, Galapagos NV on Wednesday announced it had struck a deal with Blood Centers of America to open up dozens of manufacturing sites for its cell-based medicines around the U.S.

Galapagos said it will rely on the partnership, the financial terms of which were not disclosed, as it moves its CAR-Ts for different cancers into pivotal studies and could also help launch those medicines should they win approval. The Belgian company framed the collaboration as one that could help overcome the limitations that have held back access to existing CAR-T therapies from other companies.

CAR-Ts have proven to be potent treatments for certain cancers, but they are complicated medicines to make. Immune cells have to be removed from a patient, shipped to specialty sites, where they’re engineered with cancer-killing abilities, and then returned to the hospital for infusion back into patients. The process, which can take weeks if not months, has put a crunch on the number of patients companies and hospitals are able to treat.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： JPM 2024: Biotech’s most prolific dealmaker sees a rosy 2024

Wikipedia

WSS

Readout Newsletter: Cytokinetics and Novartis' starcrossed tale

10 million people disenrolled from Medicaid over past six months

Boston Scientific acquires urology company Axonics for $3.7 billion

Profiling embryos to choose those with higher IQs is almost a reality

Physician assistants need a new name. Here's what it should be

FDA approves Recor Medical high blood pressure device

hotspot

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Apple is now the first public company to be valued at $3 trillion

American taxpayers paid $1.8 trillion in health care costs in 2022

23andMe had bad news about my health. I wish a person had delivered it

AstraZeneca CEO says participant had neurological symptoms, could be discharged today

Anesthesiologist group: stop taking Ozempic before surgery

Abortion clinic in Cancun will cater to Americans

State Dept. review finds Biden bears some blame for Afghanistan failures

Biotech incubator Curie.Bio graduates its first startup

Medical records are filled with copy

Allen Institute goes after foundational questions, CEO Costa says

explore

STAT Virtual Event: JPM Recap, Live!

Life science postdocs should get big pay hike, NIH panel says

JPM pitch from hospitals? Revenue streams outside of patient care

JPM pitch from hospitals? Revenue streams outside of patient care

Stories you might have missed in 2023: health, science, medicine

10 million people disenrolled from Medicaid over past six months

leisure time

knowledge

Wikipedia

explore